{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T02:41:31Z","timestamp":1768099291249,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.molmed.2007.02.003","type":"journal-article","created":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T15:26:17Z","timestamp":1172589977000},"page":"150-157","source":"Crossref","is-referenced-by-count":24,"title":["Fast, hungry and unstable: finding the Achilles\u2019 heel of small-cell lung cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Christine L.","family":"Hann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2007.02.003_bib1","unstructured":"American Cancer Society (2006) Cancer Facts and Figures 2006, American Cancer Society"},{"key":"10.1016\/j.molmed.2007.02.003_bib2","doi-asserted-by":"crossref","unstructured":"Navada, S. et al. (2006) Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end-results (SEER) database. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 24 (18S), 7082","DOI":"10.1200\/jco.2006.24.18_suppl.7082"},{"key":"10.1016\/j.molmed.2007.02.003_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.6004\/jnccn.2006.0050","article-title":"Small cell lung cancer clinical practice guidelines in oncology","volume":"4","author":"Johnson","year":"2006","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.molmed.2007.02.003_bib4","first-page":"188","article-title":"Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications","volume":"9","author":"Micke","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib5","first-page":"2241","article-title":"Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer","volume":"9","author":"Blackhall","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/annonc\/mdg253","article-title":"CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma","volume":"14","author":"Potti","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib7","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1038\/sj.onc.1203698","article-title":"Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571","volume":"19","author":"Wang","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2007.02.003_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ijc.20652","article-title":"In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy","volume":"113","author":"Decaudin","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib9","first-page":"5880","article-title":"Phase II study of imatinib in patients with small cell lung cancer","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib10","doi-asserted-by":"crossref","unstructured":"Schneider, B.J. et al. (2006) Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 24 (18S), 17089","DOI":"10.1200\/jco.2006.24.18_suppl.17089"},{"key":"10.1016\/j.molmed.2007.02.003_bib11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.21000","article-title":"Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial","volume":"103","author":"Krug","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib12","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib13","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1357-2725(99)00089-8","article-title":"HGF: a multifunctional growth factor controlling cell scattering","volume":"31","author":"Stella","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.molmed.2007.02.003_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.1993.7","article-title":"Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor\/scatter factor and stem cell factor, in SCLC cell lines and xenografts","volume":"67","author":"Rygaard","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib15","first-page":"6272","article-title":"c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions","volume":"63","author":"Ma","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib16","first-page":"7345","article-title":"A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo","volume":"63","author":"Christensen","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib17","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1073\/pnas.0508776103","article-title":"Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752","volume":"103","author":"Smolen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.02.003_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/0008-5472.CAN-05-3329","article-title":"Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor\/c-Met-dependent human tumors","volume":"66","author":"Burgess","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib19","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-05-1793","article-title":"Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts","volume":"12","author":"Kim","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib20","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/S0021-9258(17)35956-2","article-title":"Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs","volume":"261","author":"Sausville","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.02.003_bib21","first-page":"5205","article-title":"Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines","volume":"51","author":"Cardona","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib22","doi-asserted-by":"crossref","first-page":"18771","DOI":"10.1016\/S0021-9258(18)55129-2","article-title":"Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells","volume":"266","author":"Corjay","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.02.003_bib23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/316823a0","article-title":"Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer","volume":"316","author":"Cuttitta","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2007.02.003_bib24","doi-asserted-by":"crossref","first-page":"23901","DOI":"10.1074\/jbc.274.34.23901","article-title":"Multiple protein kinase pathways are involved in gastrin-releasing peptide receptor-regulated secretion","volume":"274","author":"Hellmich","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.02.003_bib25","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1038\/sj.onc.1208581","article-title":"Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo","volume":"24","author":"Martinez","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2007.02.003_bib26","first-page":"1798","article-title":"[Psi 13,14] bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo","volume":"51","author":"Mahmoud","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1073\/pnas.94.3.956","article-title":"Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095","volume":"94","author":"Halmos","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.02.003_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1378\/chest.112.1.256","article-title":"Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer","volume":"112","author":"Kelley","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.molmed.2007.02.003_bib29","first-page":"3385","article-title":"Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer","volume":"5","author":"Chaudhry","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib30","first-page":"5302","article-title":"A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines","volume":"55","author":"Sepp-Lorenzino","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/annonc\/mdh315","article-title":"Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer","volume":"15","author":"Heymach","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0889-8588(02)00051-5","article-title":"Clinical development of mammalian target of rapamycin inhibitors","volume":"16","author":"Dancey","year":"2002","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.molmed.2007.02.003_bib33","first-page":"5239","article-title":"The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway","volume":"58","author":"Moore","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib34","doi-asserted-by":"crossref","first-page":"8683","DOI":"10.1038\/sj.onc.1205939","article-title":"In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways","volume":"21","author":"Kraus","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2007.02.003_bib35","first-page":"913","article-title":"Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy","volume":"1","author":"Krystal","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molmed.2007.02.003_bib36","unstructured":"Pandya, K.J. et al. (2005) A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings 23 (16S), 7005"},{"key":"10.1016\/j.molmed.2007.02.003_bib37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.hoc.2004.06.005","article-title":"Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer","volume":"18","author":"Blackhall","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.molmed.2007.02.003_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2169\/internalmedicine.44.26","article-title":"Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients","volume":"44","author":"Hasegawa","year":"2005","journal-title":"Intern. Med."},{"key":"10.1016\/j.molmed.2007.02.003_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/07357900600814771","article-title":"Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer","volume":"24","author":"Tas","year":"2006","journal-title":"Cancer Invest."},{"key":"10.1016\/j.molmed.2007.02.003_bib40","doi-asserted-by":"crossref","unstructured":"Patton, J.F. et al. (2006) Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): update of a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings, Part 1 24 (18S), 7085","DOI":"10.1200\/jco.2006.24.18_suppl.7085"},{"key":"10.1016\/j.molmed.2007.02.003_bib41","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1158\/1078-0432.CCR-05-0674","article-title":"Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice","volume":"11","author":"Yano","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib42","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.02.003_bib43","unstructured":"Lee, S.M. et al. (2002) A phase II study of carboplatin\/etoposide with thalidomide in small cell lung cancer (SCLC). Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology 21, 313a"},{"key":"10.1016\/j.molmed.2007.02.003_bib44","unstructured":"Pujol, J.L. et al. (2006) A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04 - IFCT 00-01. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 24 (18S), 7057"},{"key":"10.1016\/j.molmed.2007.02.003_bib45","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1054\/bjoc.2001.2137","article-title":"Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer","volume":"85","author":"Shou","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib46","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1200\/JCO.2002.02.108","article-title":"Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer","volume":"20","author":"Shepherd","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib47","first-page":"503","article-title":"High prevalence of bcl-2 oncoprotein expression in small cell lung cancer","volume":"15","author":"Higashiyama","year":"1995","journal-title":"Anticancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1711770206","article-title":"Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas","volume":"177","author":"Jiang","year":"1995","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2007.02.003_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1139\/bcb-78-2-119","article-title":"Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line","volume":"78","author":"Luo","year":"2000","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.molmed.2007.02.003_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000063873","article-title":"Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells","volume":"48","author":"Guensberg","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.molmed.2007.02.003_bib51","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jnci\/89.14.1027","article-title":"Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence","volume":"89","author":"Ziegler","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.molmed.2007.02.003_bib52","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.2004.10.148","article-title":"Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer","volume":"22","author":"Rudin","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib53","unstructured":"Rudin, C.M. et al. (2002) Phase I study of G3139, a Bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with previously untreated extensive stage small cell lung cancer. Eur J Cancer 38 S7, 147"},{"key":"10.1016\/j.molmed.2007.02.003_bib54","first-page":"662s","article-title":"CALGB 30103: a randomized phase II study of carboplatin and etoposide with or without G3139 in patients with extensive stage small cell lung cancer","volume":"22","author":"Rudin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib55","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1099191","article-title":"Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix","volume":"305","author":"Walensky","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.molmed.2007.02.003_bib56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2007.02.003_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev.med.47.1.285","article-title":"Clinical implications of the p53 gene","volume":"47","author":"Sidransky","year":"1996","journal-title":"Annu. Rev. Med."},{"issue":"2, Suppl 4","key":"10.1016\/j.molmed.2007.02.003_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2001.25738","article-title":"Molecular genetics of small cell lung carcinoma","volume":"28","author":"Wistuba","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib59","first-page":"2287","article-title":"Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene","volume":"54","author":"Fujiwara","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib60","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1089\/hum.1994.5.9-1079","article-title":"Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer","volume":"5","author":"Wills","year":"1994","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2007.02.003_bib61","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1046\/j.1365-2249.1999.00913.x","article-title":"Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses","volume":"117","author":"Ishida","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molmed.2007.02.003_bib62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.gt.3301670","article-title":"An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53","volume":"9","author":"Nikitina","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2007.02.003_bib63","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib64","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1038\/sj.onc.1205836","article-title":"Chromosomal imbalances in human lung cancer","volume":"21","author":"Balsara","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2007.02.003_bib65","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1349-7006.1998.tb00519.x","article-title":"A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II\u2013DNA complex","volume":"89","author":"Hanada","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib66","article-title":"Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study","author":"Yana","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.molmed.2007.02.003_bib67","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/annonc\/mdi081","article-title":"Phase I\u2013II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer","volume":"16","author":"Ohe","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib68","doi-asserted-by":"crossref","unstructured":"Seto, T. et al. (2006) Phase II study of amrubicin, a new active drug in refractory or relapsed small-cell lung cancer (SCLC): Thoracic Oncology Research Group Trial 0301. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 24 (18S), 7060","DOI":"10.1200\/jco.2006.24.18_suppl.7060"},{"key":"10.1016\/j.molmed.2007.02.003_bib69","doi-asserted-by":"crossref","unstructured":"Kato, T. et al. (2006) Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 24 (18S), 7061","DOI":"10.1200\/jco.2006.24.18_suppl.7061"},{"key":"10.1016\/j.molmed.2007.02.003_bib70","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1101\/sqb.2005.70.030","article-title":"Telomerase and cancer stem cells","volume":"70","author":"Armanios","year":"2005","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.molmed.2007.02.003_bib72","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/345458a0","article-title":"Telomeres shorten during ageing of human fibroblasts","volume":"345","author":"Harley","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2007.02.003_bib73","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00262-006-0145-7","article-title":"Telomerase peptide vaccination: a phase I\/II study in patients with non-small cell lung cancer","volume":"55","author":"Brunsvig","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2007.02.003_bib74","first-page":"393","article-title":"Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications","volume":"150","author":"Cagle","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2007.02.003_bib75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","article-title":"Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model","volume":"4","author":"Meuwissen","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2007.02.003_bib76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/cc.4.2.1414","article-title":"Proteasome inhibition in the treatment of cancer","volume":"4","author":"Richardson","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.molmed.2007.02.003_bib77","first-page":"1145","article-title":"Mechanisms of proteasome inhibitor PS-341-induced G(2)\u2013M-phase arrest and apoptosis in human non-small cell lung cancer cell lines","volume":"9","author":"Ling","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib78","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.lungcan.2005.01.006","article-title":"Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer","volume":"49","author":"Mortenson","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib79","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2007.02.003_bib80","first-page":"620","article-title":"Modulation of the c-Met\/hepatocyte growth factor pathway in small cell lung cancer","volume":"8","author":"Maulik","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.seminoncol.2006.04.001","article-title":"Heat shock protein 90: a unique chemotherapeutic target","volume":"33","author":"Cullinan","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib82","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/emboj\/cdg228","article-title":"Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression","volume":"22","author":"Christofori","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.molmed.2007.02.003_bib83","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1084\/jem.169.6.2233","article-title":"Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule","volume":"169","author":"Lanier","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2007.02.003_bib84","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/1097-0142(19881101)62:9<1939::AID-CNCR2820620912>3.0.CO;2-N","article-title":"Immunophenotype of small cell lung carcinoma. Expression of NKH-1 and transferrin receptor and absence of most myeloid antigens","volume":"62","author":"Doria","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib85","doi-asserted-by":"crossref","unstructured":"Fossella, F. et al. (2005) Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings 23 (16S), 7159","DOI":"10.1200\/jco.2005.23.16_suppl.7159"},{"key":"10.1016\/j.molmed.2007.02.003_bib86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0169-5002(99)00107-5","article-title":"Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues","volume":"28","author":"Brezicka","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0169-5002(97)00049-4","article-title":"Ganglioside expression in lung cancer cell lines","volume":"18","author":"Fuentes","year":"1997","journal-title":"Lung Cancer"},{"key":"10.1016\/j.molmed.2007.02.003_bib88","first-page":"1319","article-title":"Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin","volume":"5","author":"Grant","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2007.02.003_bib89","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1200\/JCO.2005.17.186","article-title":"Phase III study of adjuvant vaccination with Bec2\/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)","volume":"23","author":"Giaccone","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2007.02.003_bib90","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","article-title":"Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines","volume":"9","author":"Lee","year":"2006","journal-title":"Cancer Cell"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491407000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491407000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T05:01:54Z","timestamp":1628485314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491407000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S1471491407000238"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2007.02.003","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}